Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
January 06 2020 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that
management will present at the 38th Annual J.P. Morgan Healthcare
Conference on Monday, January 13, 2020 at 2:30 p.m. Pacific Time.
Both the presentation and question and answer session that follows
at 3:00 p.m. will be webcast live and available for replay from
Seattle Genetics’ website at www.seattlegenetics.com in the
Investors section.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative medicines
targeting cancer to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab
vedotin-ejfv) use the company’s industry-leading antibody-drug
conjugate (ADC) technology designed to bring a powerful medicine
directly to cancer cells. ADCETRIS is approved for the treatment of
several types of CD30-expressing lymphomas, and PADCEV is approved
to treat adults with metastatic urothelial cancer. In addition,
investigational agent tucatinib, a small molecule tyrosine kinase
inhibitor, is in late-stage development for HER2-positive
metastatic breast cancer, and in clinical development for
metastatic colorectal cancer. The company is headquartered in
Bothell, Washington, and has offices in California, Switzerland and
the European Union. For more information on our robust pipeline,
visit www.seattlegenetics.com and follow @SeattleGenetics on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005191/en/
Investors: Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024